Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis
Open Access
- 21 January 2005
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 7 (2) , R349-58
Abstract
Rheumatoid arthritis (RA) is a highly heterogeneous disease with respect to its joint destructivity. The reasons underlying this heterogeneity are unknown. Deficient apoptosis in rheumatoid synovial tissue has been recently demonstrated. We have therefore decided to study the synovial expression of survivin, a key member of the apoptosis inhibitor family. The levels of survivin and antibodies against survivin were assessed by an ELISA in matched blood and synovial fluid samples collected from 131 RA patients. Results were related to joint erosivity at the time of sampling. Monocytes were transfected with survivin anti-sense oligonucleotides and were assessed for their ability to produce inflammatory cytokines. Survivin levels were significantly higher in patients with destructive disease as compared with in RA patients displaying a non-erosive disease. High survivin levels were an independent prognostic parameter for erosive RA. In contrast, high levels of antibodies against survivin were found in patients with non-erosive RA, and were negatively related to erosivity. Survivin levels in RA patients were influenced by treatment, being significantly lower among patients treated with disease-modifying anti-rheumatic drugs. Specific suppression of survivin mRNA resulted in downregulation of IL-6 production. We conclude that survivin determines the erosive course of RA, whereas survivin antibodies lead to a less aggressive course of the disease. These findings together with decreased survivin levels upon disease-modifying anti-rheumatic drug treatment, and the downregulation of inflammatory response using survivin anti-sense oligonucleotides, suggest that extracellular survivin expression mediates the erosive course of joint disease whereas autoimmune responses to the same molecule, manifested as survivin targeting antibodies, mediate protection.Keywords
This publication has 36 references indexed in Scilit:
- p53 in rheumatoid arthritis synovial fibroblasts at sites of invasionAnnals of the Rheumatic Diseases, 2003
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and OutcomeJournal of Urology, 2003
- Survivin study: What is the next wave?Journal of Cellular Physiology, 2003
- Apoptosis and melanoma: molecular mechanismsThe Journal of Pathology, 2003
- FLICE‐inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritisArthritis & Rheumatism, 2002
- Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53Journal of Biological Chemistry, 2002
- Inhibition of T cell apoptosis in the rheumatoid synovium.Journal of Clinical Investigation, 1997
- Functional discrimination between interleukin 6 and interleukin 1European Journal of Immunology, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988